Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07733089 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Zealand Pharma
13 trials monitored
See 1 trial at risk
Psoriasis
591 trials monitored
See 24 trials at risk
The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.
Trial Details
NCT Number NCT07733089
Lead Sponsor Zealand Pharma
Collaborators: Centre for Human Drug Research, Netherlands, ICON Clinical Research
Conditions
(from sponsor)		 Plaque Psoriasis
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov